SCIENTIFIC PRESENTATIONS

ASGCT 2021

A Targeted AAV Gene Therapy Product Candidate, 4D-310, for the Treatment of Fabry Disease: Intravenous Biodistribution, Transgene Expression & Safety in Non-Human Primates

Kevin Wittlesey, et al. Presented at the 24th Annual American Society of Gene & Cell Therapy (ASGCT) Meeting, May 11-14, 2021.

ATS 2021

Identification and Characterization of a Novel AAV Capsid & Product for the Treatment of Cystic Fibrosis Lung Disease

Melissa A. Calton, et al. Presented at the American Thoracic Society (ATS) 2021 Virtual Conference, May 14-19, 2021.

ASGCT 2020

Directed Evolution of AAV Targeting Lung Epithelia Using Aerosol Delivery Identifies 4D-A101, a Variant Demonstrating Robust Gene Delivery in Non-Human Primates

Melissa Kotterman, et al. Presented at the 23rd Annual American Society of Gene & Cell Therapy (ASGCT) Meeting, May 12-15, 2020.

In Vitro Fabry Disease Correction in Patient iPSC-Derived Cardiomyocytes and Endothelial Cells Using an Evolved and Optimized AAV Gene Therapeutic (4D-310)

Chris Schmitt, et al. Poster presented at the 23rd Annual American Society of Gene & Cell Therapy (ASGCT) Meeting, May 12-15, 2020.

Highly-Evolved Novel AAV Gene Therapy Directly Addresses Fabry Disease Pathology In Vivo by Cell Autonomous Expression in the Heart and Other Target Organs

Kevin Wittlesey, et al. Poster presented at the 23rd Annual American Society of Gene & Cell Therapy (ASGCT) Meeting, May 12-15, 2020.

4D-C102, a Novel Muscle-Tropic AAV Variant Demonstrates Superior Gene Delivery in Cardiac and Skeletal Muscle Tissues Versus Wild-Type AAV in Human Cells and Non-Human Primates

Melissa Kotterman, et al. Poster presented at the 23rd Annual American Society of Gene & Cell Therapy (ASGCT) Meeting, May 12-15, 2020.